** Shares of gene therapy developer bluebird bio Inc

fall ~10% to record low of 32 cents

** On Thursday, co posted Q3 sales of $10.6 mln, missing analysts est of $18.1 mln - LSEG data

** BofA Global Research downgrades BLUE to "neutral" from "buy" and cuts its estimate for peak revenue of Lyfgenia, co's gene therapy for sickle cell disease, to $540 mln from $730 mln

** Brokerage also cuts its estimate for co's 2025 revenue to $150 mln from ~$190 mln

** Lyfgenia received FDA approval in Dec last year, making it the biggest product for BLUE so far due to large patient population

** Two of 11 brokerages rate the stock "buy" or higher, 6 "hold" and 3 "sell; their median PT is $1.51 - LSEG data

** BLUE stock down ~76% YTD, including session gains

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com))